ITHACA, N.Y. -- Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been granted six additional patents for its core microfluidic device, the Chemistry and Reagent Device, or CARD(R). One patent was issued Feb. 11, while the other five have been allowed but not yet issued.
The Rheonix CARD is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention.
Once a raw sample is placed on the CARD, the automated EncompassMDx(tm) platform runs through the process of sample extraction, DNA purification, amplification and detection. The sample-to-result solution eliminates the need for multiple pieces of existing equipment, helping to make the testing process quicker, more efficient, less expensive and less likely to result in human error.
The issued patent, U.S. Patent No. 8,646,482, “Microfluidic Pump and Valve Structures and Fabrication Methods,” covers the CARD’s microfluidic component and protects wider material choices and fluidic microfeatures for the CARD cartridge. It is the sixth in a series of patents directed toward the CARD.
The other five allowed patent applications span Rheonix’s capabilities, including lamination techniques, extension of the core microfluidic device, configurations of microfluidic systems and assay techniques for improved nucleic acid purification methods. Taken together, the allowed patent applications highlight the continued novelty of Rheonix’s devices and their utility for diagnostic testing. The five patents are as follows:
* 13/010,014, “Latent Solvent-Based Microfluidic Apparatus, Methods and Applications”
* 13/185,619, “Laminated Microfluidic Strucutres and Method for Making”
* 13/662,824, “Microfluidic Pump and Valve Structures and Fabrication Methods”
* 13/759,131, “Microfluidic Chips and Assay Systems”
* 13/400,857, “Microfluidic Device-Based Nucleic Acid Purification Method”
“These patents further extend and enhance Rheonix’s core device and assay systems, which provide a versatile platform for the development of commercially viable diagnostic products,” said Tony Eisenhut, president of Rheonix.
These patents join Rheonix’s previously issued 14 patent families comprising 15 domestic patents and 17 pending patents.
For more information on Rheonix and the Rheonix CARD device, please visit www.rheonix.com.
About Rheonix: Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx(tm) platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD(R) cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.
Christopher Powers
Public Relations Account Manager
Pinckney Hugo Group
760 West Genesee Street
Syracuse, NY 13204
315-478-6700
cpowers@pinckneyhugo.com
On behalf of Rheonix
Help employers find you! Check out all the jobs and post your resume.
